Izumis

Metformin Hydrochloride, the active ingredient in Izumis, is a biguanide presented as an oral tablet for oral use. It treats type 2 diabetes mellitus in adults. GNH USA supplies Izumis as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Metformin Hydrochloride is used to improve glycaemic control in conditions related to insulin resistance and hyperglycaemia. - Type 2 diabetes mellitus: lowers fasting and post‑prandial blood glucose levels. - Prediabetes: delays progression to overt diabetes by improving insulin sensitivity. - Polycystic ovary syndrome (PCOS): reduces insulin resistance and helps regulate menstrual cycles.

Metformin Hydrochloride may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Gastrointestinal upset: nausea, abdominal discomfort, or loss of appetite. - Diarrhoea: loose stools occurring especially after dose initiation. - Metallic taste: transient alteration in taste perception. - Mild hypoglycaemia: when combined with other glucose‑lowering agents.

Serious or Rare Side Effects: - Lactic acidosis: a rare but potentially fatal accumulation of lactate. - Severe skin reactions: such as Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Hepatotoxicity: liver enzyme elevations indicating liver injury. - Vitamin B12 deficiency: long‑term therapy may reduce B12 absorption. - Pancreatitis: inflammation of the pancreas in rare cases.

Metformin Hydrochloride requires careful monitoring in several clinical situations. - Renal function: assess creatinine clearance before initiation and periodically thereafter. - Hepatic function: evaluate liver enzymes, especially in patients with existing liver disease. - Cardiovascular status: avoid in patients with unstable or acute heart failure. - Pregnancy: use only if clearly needed; category B indicates no proven risk in animal studies. - Vitamin B12 monitoring: consider periodic testing during long‑term therapy. - Store at room temperature: keep in the original container, protect from moisture and heat.

Metformin Hydrochloride can interact with other medicines, altering its efficacy or safety.

Major Interactions (Avoid): - Iodinated contrast agents: increase risk of lactic acidosis; discontinue metformin before and after imaging. - Cimetidine: may raise metformin plasma concentrations. - Alcohol: potentiates risk of lactic acidosis.

Moderate Interactions (Monitor Closely): - Sulfonylureas or insulin: heightened risk of hypoglycaemia; dose adjustments may be required. - Beta‑blockers: may mask hypoglycaemic symptoms. - ACE inhibitors or ARBs: monitor renal function as combined effect may affect clearance.